UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 13 November 2026, London UK
Bexsero
(4CMenB) receives positive CHMP
opinion for one-dose Meningitis B booster for 10+ year
olds
●
Recommendation based on data showing immune memory
established following vaccination in infancy can be boosted up to
19 years later1
●
Once approved, the single-dose booster could help
vaccination programmes maintain protection into adolescence, when
disease incidence reaches a second peak2
GSK plc (LSE/NYSE: GSK) today announced the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency
(EMA) has recommended updating the Bexsero label to include a single booster dose for
individuals aged 10 years and older who were previously vaccinated
at least two years earlier with Bexsero. The recommendation is supported by data showing
that immune memory established following primary vaccination in
infancy can be boosted with a single dose up to 19 years
later1.
Sanjay Gurunathan, Senior Vice President, R&D Vaccines &
Infectious Diseases, GSK, said: “As the first generation of children
vaccinated against MenB in infancy reaches adolescence,
today’s positive CHMP opinion supports maintaining protection
with a single booster dose during a second period in life of
increased disease risk. If adopted, adolescent boosters could help
reduce the overall burden of Invasive Meningococcal Disease (IMD)
in countries with established infant MenB
programmes”.
While Invasive Meningococcal Disease (IMD) is uncommon, it can
progress rapidly and become life-threatening3.
Disease incidence is highest in infants and young children, with a
second peak in adolescents and young adults2.
Adolescents are more likely to catch or pass on these bacteria
because they often spend more time socialising, live closely with
others, and may share personal items4.
In Europe, serogroup B is the leading cause of invasive
meningococcal disease in all age groups under 65
years2.
The CHMP’s positive opinion is based on data from Men-B-096,
a Phase IIIb open label, multi-centre study which assessed the
immune response and safety of a single booster dose of
Bexsero
in healthy individuals aged 10-20
years who previously completed their primary vaccination series
with Bexsero. The study met its primary endpoint. The safety
and reactogenicity of a single booster dose is consistent with the
known safety profile of Bexsero in this age group.
About Men-B-096
Men-B-096 is a Phase IIIb, open label, multi-centre study assessing
the immune response and safety of a single dose of
Bexsero
in healthy children aged 10-20 years.
The study enrolled 312 participants across Finland, Italy, Spain
and the UK, including 234 who had received Bexsero during infancy and 78 who had not previously
received a meningococcal B vaccine. The primary endpoint was to
assess the superiority of the immune response to a single booster
dose in previously vaccinated participants compared with a first
dose in adolescents who hadn’t received a MenB vaccine in the
past.
About invasive meningococcal disease (IMD)
IMD is an uncommon but serious infection caused by
Neisseria
meningitidis that can present
as meningitis and/or septicaemia (blood poisoning). Although anyone
can develop the disease, incidence is highest among infants and
young children, with a second peak in adolescents and young
adults2.
IMD can progress rapidly and may result in death or long-term
complications despite treatment.5,6
About Bexsero (4CMenB)
Bexsero is registered in
61 countries for the prevention of Invasive Meningococcal Disease
(IMD) caused by Neisseria
meningitidis serogroup B.
In Europe, it is included in 15 national and/or regional
immunisation programmes for infants, and 3 national immunisation
programmes for adolescents, with additional infant vaccination
programmes funded at a regional level in some
countries7.
Around 140 million doses of Bexsero have
been distributed globally since 20158.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Madison Goring
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Alison Hunt
|
+1 540 742 3391
|
(Washington DC)
|
|
|
Stephanie Caccomo
|
+1 202 893 2840
|
(Washington DC)
|
|
Investor Relations:
|
James Dodwell
|
+44 (0) 7881 269066
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Joanna Tuplin
|
+44 (0) 7788 351650
|
(London)
|
|
|
Sam Piper
|
+44 (0) 7824 525779
|
(London)
|
|
|
Dan Smith
|
+44 (0) 7823 523885
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the “Risk
Factors” section in GSK’s Annual Report on Form 20-F
for 2025, and GSK’s Q3 Results for 2026.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London WC1A 1DG
References
1.
Icardi
G, Martinón-Torres F, Salamanca de la Cueva I, et al. A single
adolescent dose of 4CMenB effectively boosts immune responses up to
19 years after priming in infancy: Results from a phase 3b,
open-label, multicenter study. Presented at the International
Pathogenic Neisseria Conference (IPNC), Busselton, Western
Australia, Australia, 13-17 September 2026. Abstract
141317.
2.
European Centre for Disease Prevention and
Control. Invasive meningococcal disease - Annual Epidemiological
Report for 2024. Stockholm: ECDC; 2026. Accessed November
2026. https://www.ecdc.europa.eu/en/publications-data/invasive-meningococcal-disease-annual-epidemiological-report-2024
3.
European Centre for Disease Control and
Prevention. Disease information about meningococcal disease, 28
November 2023. Available at: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet.
Accessed November 2026.
4.
Centers for Disease Control and Prevention. Risk
Factors for Meningococcal Disease. Available at:
https://www.cdc.gov/meningococcal/risk-factors/index.html.
Accessed November 2026
5.
Thompson
MJ, et al. Clinical recognition of meningococcal disease in
children and adolescents. Lancet.
2006;367(9508):397-403.
6.
McMillan
M, McDonough J, Angliss M, Buttery J, Saunders L, Mathew SM, Shaw
D, Gordon D, Warner MS, Nelson R, Hannah R, Marshall HS. Exploring
the Health-Related Quality of Life and the Lived Experience of
Adolescents Following Invasive Meningococcal Disease. Healthcare
(Basel). 2024 May 24;12(11):1075. doi: 10.3390/healthcare12111075.
PMID: 38891151; PMCID: PMC11172222.
7.
GSK
Data on file, REF-343997. Bexsero is included in 15 national
immunisation programmes for infants, and 3 national immunisation
programmes for adolescents
8.
GSK
Data on file, REF-310855. 140 million doses shipped from 2015 to
October 2025.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
13, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|